» Articles » PMID: 33347911

Vitamin E Delta-tocotrienol and Metabolite 13'-carboxychromanol Inhibit Colitis-associated Colon Tumorigenesis and Modulate Gut Microbiota in Mice

Overview
Journal J Nutr Biochem
Date 2020 Dec 21
PMID 33347911
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The gut microbiota play important roles in colon cancer. Vitamin E δ-tocotrienol (δTE) and its metabolite δTE-13'-carboxychromanol (δTE-13') are known to have cancer-preventive effects, but their impact on gut flora during tumorigenesis and the role of the metabolite in δTE's beneficial effects remain to be determined. In the murine colitis-associated colon cancer (CAC) induced by azoxymethane (AOM) and dextran sulfate sodium (DSS), we show that δTE and δTE-13' inhibited the multiplicity of large adenomas (>2 mm) by 34% (P<.05) and 55% (P<.01), respectively, compared to the control diet. δTE-13' diminished AOM/DSS-increased GM-CSF and MCP-1, and δTE decreased IL-1β. Using 16S rRNA gene sequencing of fecal DNAs, we observe that δTE and δTE-13' modulated the composition but not the richness of gut microbes compared to the control. Both δTE and δTE-13' enhanced potentially beneficial Lactococcus and Bacteroides. The elevation of Lactococcus positively correlated with fecal concentrations of δTE-13' and its hydrogenated metabolite, suggesting that the metabolite may contribute to δTE's modulation of gut microbes. Furthermore, δTE-13' counteracted AOM/DSS-induced depletion of Roseburia that is known to be decreased in patients with inflammatory bowel diseases. δTE uniquely elevated (Eubacterium) coprostanoloigenes. Our study demonstrates that δTE and δTE-13' inhibited tumorigenesis, suppressed pro-inflammatory cytokines and modulated gut microbiota in a murine CAC model. These findings uncover new and distinct activities of δTE and δTE-13' and support the notion that the metabolite may play a role in δTE's anticancer and modulation of gut microbes.

Citing Articles

Exploring micronutrients and microbiome synergy: pioneering new paths in cancer therapy.

Bhatnagar K, Jha K, Dalal N, Patki N, Gupta G, Kumar A Front Immunol. 2024; 15:1442788.

PMID: 39676876 PMC: 11638209. DOI: 10.3389/fimmu.2024.1442788.


Single-centre, randomised clinical trial of the immunomodulatory mechanisms of daily supplementation of palm tocotrienol-rich fraction in healthy human volunteers following influenza vaccination.

Radhakrishnan A, Ahmad B, Selvaduray K, Abdul Hafid S, Palanisamy U, Zsien Zhin C F1000Res. 2024; 13:135.

PMID: 39268057 PMC: 11391185. DOI: 10.12688/f1000research.137005.1.


Insights into the Anticancer Mechanisms Modulated by Gamma and Delta Tocotrienols in Colorectal Cancers.

Khalid A, Zaidan T, Bhuvanendran S, Magalingam K, Mohamedahmed S, Ramdas P Nutr Rev. 2024; 83(3):e1295-e1310.

PMID: 39181121 PMC: 11819494. DOI: 10.1093/nutrit/nuae108.


Health Benefits of Palm Tocotrienol-Rich Fraction: A Systematic Review of Randomized Controlled Trials.

Looi A, Palanisamy U, Moorthy M, Radhakrishnan A Nutr Rev. 2024; 83(2):307-328.

PMID: 38916919 PMC: 11723135. DOI: 10.1093/nutrit/nuae061.


The Potential Role of Vitamin E and the Mechanism in the Prevention and Treatment of Inflammatory Bowel Disease.

Wu Q, Luo Y, Lu H, Xie T, Hu Z, Chu Z Foods. 2024; 13(6).

PMID: 38540888 PMC: 10970063. DOI: 10.3390/foods13060898.